Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics, Inc. (Nasdaq: AKRO) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. This news page aggregates company announcements, clinical updates and financial disclosures so readers can follow how Akero’s development programs progress over time.
Akero’s news flow is heavily driven by data from its clinical trials. Regular press releases cover results and analyses from the Phase 2b HARMONY and SYMMETRY studies, which evaluate EFX in patients with pre-cirrhotic (F2–F3) MASH and compensated cirrhosis (F4) due to MASH, respectively. Updates often include histology outcomes, non-invasive fibrosis markers, and AI-based digital pathology findings that the company uses to characterize the antifibrotic activity of EFX.
Investors and clinicians can also find announcements related to the global Phase 3 SYNCHRONY program, including enrollment milestones and planned timing of readouts for SYNCHRONY Histology, SYNCHRONY Outcomes and SYNCHRONY Real-World. In addition, Akero regularly reports quarterly financial results, business updates, and participation in major healthcare and liver disease conferences, where management presents new data and analyses.
Another key category of news involves corporate and strategic developments. Akero has announced an Agreement and Plan of Merger under which it is expected to become a wholly owned subsidiary of Novo Nordisk A/S, subject to stockholder and regulatory approvals. Readers who follow AKRO news can track updates on this proposed transaction alongside ongoing clinical and scientific disclosures. Bookmark this page to quickly access the latest company-issued information, from peer-reviewed publication announcements to conference presentations and regulatory-related communications.
Akero Therapeutics (Nasdaq: AKRO) will present results from its Phase 2a BALANCED study at the 2021 EASL Congress on June 26, showcasing efruxifermin (EFX) improvements in NASH patients with compensated cirrhosis. Additionally, two presentations will occur at the 81st ADA Meeting from June 25-29. Akero emphasizes EFX's potential to reverse liver injury, improve glycemic control, and enhance lipoprotein profiles. With ongoing Phase 2b trials, the company aims to address the unmet medical needs in NASH, particularly for patients with type 2 diabetes.
Akero Therapeutics (Nasdaq: AKRO), a biotech firm focused on cardio-metabolic therapies, will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. (ET). The company is developing treatments for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Its lead candidate, EFX, is undergoing a Phase 2b clinical trial named HARMONY, targeting NASH patients with F2/F3 fibrosis. Akero is based in South San Francisco. For more details, visit www.akerotx.com.
Akero Therapeutics (Nasdaq: AKRO) reported its first-quarter financial results for 2021, revealing significant progress in its NASH treatment program. Notably, 58% of patients treated with efruxifermin (EFX) showed improvement in fibrosis after 16 weeks, compared to 0% in the placebo group. The company has initiated two Phase 2b trials for NASH this year and plans to present additional data at upcoming conferences. Financially, Akero holds $250 million in cash, projecting sufficient funds through Q3 2023. Operating expenses rose to $15.1 million from $12.4 million year-over-year.
Akero Therapeutics (Nasdaq: AKRO) has appointed Yuan Xu, Ph.D., as an independent director to its board. Dr. Xu brings significant biopharmaceutical experience, having previously served as CEO of Legend Biotech and held senior roles at Merck, Novartis, Gilead, and GlaxoSmithKline. Her expertise will be instrumental as Akero advances its lead candidate, efruxifermin, into late-stage development for non-alcoholic steatohepatitis (NASH), a condition currently without approved therapies. This strategic move aims to bolster the company’s efforts in delivering innovative treatments.
Akero Therapeutics (Nasdaq: AKRO) announced the randomization of the first patient in its Phase 2b clinical study of Efruxifermin (EFX) for patients with F2/F3 non-alcoholic steatohepatitis (NASH), also known as the HARMONY study. This milestone reflects the company's continued progress, with screening and enrollment ahead of schedule. The trial aims to evaluate fibrosis regression after 24 weeks of treatment. EFX offers a potential new treatment option for NASH, a disease lacking FDA-approved therapies, impacting millions.
Akero Therapeutics (Nasdaq: AKRO) reported promising results from its Phase 2a clinical trial of efruxifermin (EFX) in cirrhotic patients with non-alcoholic steatohepatitis (NASH). Key findings include:
- 33% of EFX patients improved fibrosis by one stage without worsening NASH.
- 25% achieved NASH resolution.
- 58% showed histological improvements.
EFX was generally well-tolerated, with mild side effects noted. The trial's findings suggest potential for EFX as a foundational treatment for cirrhotic NASH, paving the way for further studies.
Akero Therapeutics, Inc. (Nasdaq: AKRO) announced plans to discuss new efficacy and safety data from the expansion cohort of its Phase 2a clinical trial for efruxifermin (EFX), aimed at treating adults with cirrhotic non-alcoholic steatohepatitis (NASH). The update, including biopsy results, will be presented in a press release and a webcast on March 22, 2021, at 4:30 p.m. ET. Akero is focused on developing treatments for NASH, a condition without current approved therapies.
Akero Therapeutics (Nasdaq: AKRO) reported its fourth quarter and full year financial results for 2020, showcasing promising data from the Phase 2a BALANCED study on efruxifermin (EFX) for treating NASH. Notably, 50% of patients with baseline fibrosis F2 or F3 showed a two-stage improvement in fibrosis after 16 weeks. The company holds $268.4 million in cash and equivalents at year-end. R&D expenses rose to $64.9 million, reflecting investment in EFX clinical trials. Akero plans to present more data by April 2021 and expects to complete enrollment in the Phase 2b HARMONY study this year.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming virtual investor conferences in March 2021. The Cowen 41st Annual Healthcare Conference is scheduled for March 2, while the 2021 H.C. Wainwright Global Life Sciences Conference will take place on March 9. The company will offer live webcasts of its presentations, which will be accessible through their investor relations website. Akero is focused on developing therapies for non-alcoholic steatohepatitis (NASH), with its lead program, EFX, currently in Phase 2 clinical trials.
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology firm, has announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2021, at 10:50 a.m. EST. Investors can view the live webcast through the company's website, with an archived version available for 30 days post-event.
Akero is focused on developing innovative treatments for non-alcoholic steatohepatitis (NASH) and metabolic disorders. Its lead drug candidate, Efruxifermin (EFX), is undergoing a Phase 2a clinical trial.